GATINEAU, QC – November 3, 2017 (Investorideas.com Newswire) The Hydropothecary Corporation (“Hydropothecary” or the “Company”) (TSX VENTURE: THCX) is pleased to announce the release of two new products, Decarb Micro THC and Decarb Micro CBD. Part of the Company’s unique innovative line of Decarb products, Decarb Micro THC and Decarb Micro CBD are ready-to-consume, activated medical marijuana powders.
Decarb Micro allows clients to adjust their consumption of medical cannabis through the intake of minimal amounts of THC or CBD. Periodic use of Decarb Micro allows clients to help maintain their cannabinoid levels throughout the day.
In response to the needs of medical cannabis patients, the Company’s Decarb Micro products will be priced at $3 per gram, making Decarb Micro THC and Decarb Micro CBD amongst the lowest priced premium cannabis products on the market.
“With our Decarb Micro products, we have created a much-needed offering at an affordable price point, designed to provide patients the ability to maximize the benefits of medical cannabis through greater control of their cannabinoid intake levels,” said Hydropothecary CEO and co-founder, Sebastien St-Louis.
Decarb Micro THC and Decarb Micro CBD can be used along with the Hydropothecary’s CannaCap capsules and capsule maker. Hydropothecary’s Decarb products are created by a proprietary drying method that employs exacting scientific standards to decarboxylate (decarb) the cannabis and activate the cannabinoids (THC and CBD). Micro Decarb products provide a flexible and discreet alternative to smoking, vaping and oils, since the powder can be taken in capsules or incorporated into food or drinks.
“This new release is the latest example of Hydropothecary’s on-going commitment to product innovation and our focus on customer needs. Decarb Micro THC and Decarb Micro CBD ensure our clients have flexibility together with affordable, discreet and easy-to-understand products,” noted Mr. St-Louis.
About The Hydropothecary Corporation
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides sun grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary’s branding, cannabis product offering, patient service standards and product pricing are consistent with THCX’s positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Hydropothecary Product Facts
Number of Hydropothecary medical marijuana products available: 20
Number of kosher-certified medical marijuana products currently available: 7
Price range on per gram products: $3 to $15
Release date of Elixir No.1, Canada’s first sublingual cannabis oil mist: July 2017
Number of Decarb fine milled medical marijuana products: 6
Media Contact Information
Publicity and Media Relations
Investor Relations Contact Information
Manager of Financial Reporting and Investor Relations
Investorideas.com is a listed service provider on the Canadian Securities Exchange http://thecse.com/en/services/services-for-listed-companies/investorideascom
This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Source: New feed